BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

The equity awards tie new-employee compensation to continued employment through a staged vesting schedule.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) approved restricted stock unit grants covering 147,578 common shares for new employees on November 5, 2026. The compensation committee approved the awards for 80 new employees as inducements to enter employment under Nasdaq Listing Rule 5635(c)(4).

One-fourth of each employee’s underlying shares will vest on November 16, 2027. One-twelfth of the remaining shares will vest quarterly thereafter. Each installment is subject to continued employment with BridgeBio or one of its subsidiaries on the vesting date.

Positive

None.

Negative

Minor point. Forward-looking: it has not happened yet and may not happen.Restricted stock units covering 147,578 common shares create potential dilution as the employee awards vest.

Key Figures

Employees receiving grants: 80 employees Aggregate shares: 147,578 shares Initial vesting tranche: One-fourth of shares +1 more

Employees receiving grants: 80 employees; New employees receiving inducement equity grants
Aggregate shares: 147,578 shares; Underlying the restricted stock unit awards
Initial vesting tranche: One-fourth of shares; Vests November 16, 2027, subject to continued employment
Subsequent vesting: One-twelfth of remaining shares; Vests quarterly thereafter, subject to continued employment

Historical Context

1 past event · Latest: Oct 16

1 event

Oct 16
Inducement grants

24h Move

-1.1%

Earlier inducement awards covered 57,853 shares for 32 new employees, with the same vesting structure.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units

1 terms

restricted stock units financial

"equity grants to 80 new employees in restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/06/2026 - 04:01 PM EST

PALO ALTO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on November 5, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 80 new employees in restricted stock units for an aggregate of 147,578 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on November 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates.

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Investor Relations
ir@bridgebio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many employee inducement awards did BridgeBio Pharma approve?

BridgeBio approved restricted stock units covering an aggregate of 147,578 common shares for 80 new employees. The compensation committee approved the grants on November 5, 2026, as employment inducements under Nasdaq Listing Rule 5635(c)(4).

When do BridgeBio Pharma’s new employee restricted stock units vest?

One-fourth of each employee’s underlying shares will vest on November 16, 2027, followed by one-twelfth of the remaining shares quarterly thereafter. Vesting requires continued employment with BridgeBio or one of its subsidiaries on each applicable vesting date.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)